Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.,Journal of Diabetes Investigation

当前位置： X-MOL 学术 › J. Diabetes Investig. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
Journal of Diabetes Investigation ( IF 3.1 ) Pub Date : 2020-02-05 , DOI: 10.1111/jdi.13205
Daisuke Yamazaki _{1,

2} , Yoshio Konishi ₂ , Takashi Morikawa ₂ , Hideki Kobara ₃ , Tsutomu Masaki ₃ , Hirofumhi Hitomi ₄ , Kenji Osafune ₅ , Daisuke Nakano ₁ , Wararat Kittikulsuth ₁ , Akira Nishiyama ₁

Affiliation

Clinical studies have shown that treatment with inhibitors of sodium–glucose cotransporter 2 (SGLT2) significantly increases the hematocrit in patients with type 2 diabetes. To investigate whether SGLT2 inhibitors directly promote erythropoietin production independently on blood glucose reduction, the hematopoietic effect of the specific SGLT2 inhibitor, luseogliflozin, was examined in non‐diabetic rats with renal anemia.

中文翻译：

未能证实钠-葡萄糖协同转运蛋白 2 抑制剂对患有肾性贫血的非糖尿病大鼠的造血作用。

临床研究表明，钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂治疗可显着增加 2 型糖尿病患者的血细胞比容。为了研究 SGLT2 抑制剂是否独立于血糖降低直接促进促红细胞生成素产生，在患有肾性贫血的非糖尿病大鼠中检查了特异性 SGLT2 抑制剂 luseogliflozin 的造血作用。

更新日期：2020-02-05

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11